Discovery of a mitochondria-targeted fluorescent probe as TrxR inhibitors for cancer therapy

Abstract

The development of functional agents capable of targeting subcellular organelles has been an attractive strategy for precision therapy. The mitochondria-targeted fluorescent probe 6e is a new fluorescent TrxR inhibitor that can be readily monitored in vitro and in vivo, indicating the great potential of theranostic strategies for precise anticancer treatment.